Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomePreferred Shares IssuedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash from Operations: 2013-2024

Historic Cash from Operations for vTv Therapeutics (VTVT) over the last 12 years, with Dec 2024 value amounting to -$25.3 million.

  • vTv Therapeutics' Cash from Operations rose 18.64% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.8 million, marking a year-over-year increase of 10.97%. This contributed to the annual value of -$25.3 million for FY2024, which is 32.63% down from last year.
  • According to the latest figures from FY2024, vTv Therapeutics' Cash from Operations is -$25.3 million, which was down 32.63% from -$19.1 million recorded in FY2023.
  • In the past 5 years, vTv Therapeutics' Cash from Operations ranged from a high of -$16.0 million in FY2022 and a low of -$25.3 million during FY2024.
  • In the last 3 years, vTv Therapeutics' Cash from Operations had a median value of -$19.1 million in 2023 and averaged -$20.1 million.
  • As far as peak fluctuations go, vTv Therapeutics' Cash from Operations grew by 21.80% in 2020, and later tumbled by 32.63% in 2024.
  • vTv Therapeutics' Cash from Operations (Yearly) stood at -$18.0 million in 2020, then fell by 7.27% to -$19.3 million in 2021, then rose by 17.02% to -$16.0 million in 2022, then dropped by 19.09% to -$19.1 million in 2023, then plummeted by 32.63% to -$25.3 million in 2024.